{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:44:52Z","timestamp":1792143892817,"version":"4.4.0"},"publisher-location":"New York, NY","reference-count":34,"publisher":"Springer US","isbn-type":[{"value":"9781071655863","type":"print"},{"value":"9781071655870","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2027]]},"DOI":"10.1007\/978-1-0716-5587-0_12","type":"book-chapter","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:54:26Z","timestamp":1792140866000},"page":"197-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of Resazurin and ATP Detection Cell Viability Assays for Drug Sensitivity Screening in Ewing Sarcoma"],"prefix":"10.1007","author":[{"given":"Annika","family":"Jeschke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Cidre-Aranaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheraz","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"12_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Gr\u00fcnewald","year":"2018","unstructured":"Gr\u00fcnewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de \u00c1lava E, Kovar H et al. (2018) Ewing sarcoma. Nat Rev Dis Primers 4(1):5. https:\/\/doi.org\/10.1038\/s41572-018-0003-x","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"12_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10555-019-09839-9","volume":"38","author":"MML Knott","year":"2019","unstructured":"Knott MML, H\u00f6lting TLB, Ohmura S, Kirchner T, Cidre-Aranaz F, Gr\u00fcnewald TGP (2019) Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies. Cancer Metastasis Rev 38(4):625\u2013642. https:\/\/doi.org\/10.1007\/s10555-019-09839-9","journal-title":"Cancer Metastasis Rev"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.jbo.2021.100404","volume":"31","author":"G Flores","year":"2021","unstructured":"Flores G, Grohar PJ (2021) One oncogene, several vulnerabilities: EWS\/FLI targeted therapies for Ewing sarcoma. J Bone Oncol 31:100404. https:\/\/doi.org\/10.1016\/j.jbo.2021.100404","journal-title":"J Bone Oncol"},{"issue":"3","key":"12_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/2159-8290.Cd-20-0779","volume":"11","author":"TW Laetsch","year":"2021","unstructured":"Laetsch TW, DuBois SG, Bender JG, Macy ME, Moreno L (2021) Opportunities and challenges in drug development for pediatric cancers. Cancer Discov 11(3):545\u2013559. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0779","journal-title":"Cancer Discov"},{"issue":"27","key":"12_CR5","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/jco.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al. (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33(27):3036\u20133046. https:\/\/doi.org\/10.1200\/jco.2014.59.5256","journal-title":"J Clin Oncol"},{"key":"12_CR6","doi-asserted-by":"publisher","unstructured":"Z\u00f6llner SK, Amatruda JF, Bauer S, Collaud S, de \u00c1lava E, DuBois SG, et al (2021) Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med. 10(8). https:\/\/doi.org\/10.3390\/jcm10081685","DOI":"10.3390\/jcm10081685"},{"key":"12_CR7","doi-asserted-by":"publisher","unstructured":"Hesla AC, Papakonstantinou A, Tsagkozis P (2021) Current status of management and outcome for patients with Ewing sarcoma. Cancers 13(6). https:\/\/doi.org\/10.3390\/cancers13061202","DOI":"10.3390\/cancers13061202"},{"issue":"4","key":"12_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/pbc.23040","volume":"57","author":"M Stahl","year":"2011","unstructured":"Stahl M, Ranft A, Paulussen M, B\u00f6lling T, Vieth V, Bielack S et al. (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57(4):549\u2013553. https:\/\/doi.org\/10.1002\/pbc.23040","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"12_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd4366","volume":"13","author":"JG Moffat","year":"2014","unstructured":"Moffat JG, Rudolph J, Bailey D (2014) Phenotypic screening in cancer drug discovery\u2014past, present and future. Nat Rev Drug Discov 13(8):588\u2013602. https:\/\/doi.org\/10.1038\/nrd4366","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"12_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00335-y","volume":"6","author":"H Peterziel","year":"2022","unstructured":"Peterziel H, Jamaladdin N, ElHarouni D, Gerloff XF, Herter S, Fiesel P et al. (2022) Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. npj Precis Oncol 6(1):94. https:\/\/doi.org\/10.1038\/s41698-022-00335-y","journal-title":"npj Precis Oncol"},{"issue":"1","key":"12_CR11","doi-asserted-by":"publisher","first-page":"103605","DOI":"10.1016\/j.xpro.2025.103605","volume":"6","author":"J Wei","year":"2025","unstructured":"Wei J, Zhang SY, Zhou XY, Wei Y, Jia HR, Wu Q et al. (2025) Protocol to identify small-molecule inhibitors against cancer drug resistance. STAR Protoc 6(1):103605. https:\/\/doi.org\/10.1016\/j.xpro.2025.103605","journal-title":"STAR Protoc"},{"issue":"4","key":"12_CR12","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.18632\/oncotarget.23462","volume":"9","author":"M Shen","year":"2018","unstructured":"Shen M, Asawa R, Zhang YQ, Cunningham E, Sun H, Tropsha A et al. (2018) Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. Oncotarget 9(4):4758\u20134772. https:\/\/doi.org\/10.18632\/oncotarget.23462","journal-title":"Oncotarget"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"579488","DOI":"10.3389\/fonc.2021.579488","volume":"11","author":"A Nehdi","year":"2021","unstructured":"Nehdi A, Samman N, Mashhour A, Alhallaj A, Trivilegio T, Gul S et al. (2021) A Drug Repositioning Approach Identifies a Combination of Compounds as a Potential Regimen for Chronic Lymphocytic Leukemia Treatment. Front Oncol 11:579488. https:\/\/doi.org\/10.3389\/fonc.2021.579488","journal-title":"Front Oncol"},{"issue":"5","key":"12_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","volume":"130","author":"FR Weth","year":"2024","unstructured":"Weth FR, Hoggarth GB, Weth AF, Paterson E, White MPJ, Tan ST et al. (2024) Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. Br J Cancer 130(5):703\u2013715. https:\/\/doi.org\/10.1038\/s41416-023-02502-9","journal-title":"Br J Cancer"},{"issue":"6","key":"12_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","volume":"78","author":"J Boshuizen","year":"2020","unstructured":"Boshuizen J, Peeper DS (2020) Rational cancer treatment combinations: an urgent clinical need. Mol Cell 78(6):1002\u20131018. https:\/\/doi.org\/10.1016\/j.molcel.2020.05.031","journal-title":"Mol Cell"},{"issue":"1","key":"12_CR16","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.xpro.2021.101079","volume":"3","author":"C Calandrini","year":"2022","unstructured":"Calandrini C, Drost J (2022) Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities. STAR Protocols 3(1):101079. https:\/\/doi.org\/10.1016\/j.xpro.2021.101079","journal-title":"STAR Protocols"},{"issue":"20","key":"12_CR17","doi-asserted-by":"publisher","first-page":"17931","DOI":"10.1021\/acs.jmedchem.4c02052","volume":"67","author":"B Srinivasan","year":"2024","unstructured":"Srinivasan B, Lloyd MD (2024) Dose\u2013response curves and the determination of IC50 and EC50 Values. J Med Chem 67(20):17931\u201317934. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02052","journal-title":"J Med Chem"},{"key":"12_CR18","doi-asserted-by":"publisher","unstructured":"Bulut I, Lee A, Cevatemre B, Ruzic D, Belle R, Kawamura A et al (2022) Dual LSD1 and HDAC6 inhibition induces doxorubicin sensitivity in acute myeloid leukemia cells. Cancers 14(23). https:\/\/doi.org\/10.3390\/cancers14236014","DOI":"10.3390\/cancers14236014"},{"key":"12_CR19","doi-asserted-by":"crossref","unstructured":"Larsson P, Parris TZ (2023) Optimization of cell viability assays for drug sensitivity screens. In: Friedrich O, Gilbert DF (eds) Cell viability assays: methods and protocols. Springer US, New York, NY. pp 287\u2013302","DOI":"10.1007\/978-1-0716-3052-5_18"},{"issue":"14","key":"12_CR20","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.Ccr-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M (2017) Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res 23(14):3489\u20133498. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3083","journal-title":"Clin Cancer Res"},{"issue":"12","key":"12_CR21","doi-asserted-by":"publisher","first-page":"e5646","DOI":"10.1590\/1414-431x20165646","volume":"49","author":"EL Andrade","year":"2016","unstructured":"Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM et al. (2016) Non-clinical studies in the process of new drug development-Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res 49(12):e5646. https:\/\/doi.org\/10.1590\/1414-431x20165646","journal-title":"Braz J Med Biol Res"},{"key":"12_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6960-9_1","volume":"1601","author":"K Pr\u00e4bst","year":"2017","unstructured":"Pr\u00e4bst K, Engelhardt H, Ringgeler S, H\u00fcbner H (2017) Basic colorimetric proliferation Assays: MTT, WST, and Resazurin. Methods Mol Biol 1601:1\u201317. https:\/\/doi.org\/10.1007\/978-1-4939-6960-9_1","journal-title":"Methods Mol Biol"},{"key":"12_CR23","unstructured":"Riss T, Moravec R, Niles A, Duellman A, Benink H, Worzella T et al (2013) Cell viability assays. In: Markossian S, Grossman A, Baskir H et al. (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences"},{"key":"12_CR24","doi-asserted-by":"publisher","unstructured":"Strober W (2015) Trypan blue exclusion test of cell viability. Curr Protoc Immunol 111(1):A3.B.1\u2013A3.B.3.\u2002https:\/\/doi.org\/10.1002\/0471142735.ima03bs111","DOI":"10.1002\/0471142735.ima03bs111"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-61779-108-6_5","volume":"740","author":"EM Czekanska","year":"2011","unstructured":"Czekanska EM (2011) Assessment of cell proliferation with resazurin-based fluorescent dye. Methods Mol Biol 740:27\u201332. https:\/\/doi.org\/10.1007\/978-1-61779-108-6_5","journal-title":"Methods Mol Biol"},{"issue":"5","key":"12_CR26","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/molecules28052283","volume":"28","author":"B Vieira-da-Silva","year":"2023","unstructured":"Vieira-da-Silva B, Castanho MARB (2023) Resazurin reduction-based assays revisited: guidelines for accurate reporting of relative differences on metabolic status. Molecules. 28(5):2283","journal-title":"Molecules."},{"key":"12_CR27","doi-asserted-by":"publisher","unstructured":"Funk CM, Ehlers AC, Orth MF, Aljakouch K, Li J, H\u00f6lting TL et al (2025) High 4E-BP1 expression associates with chromosome 8 gain and CDK4\/6 sensitivity in Ewing sarcoma. J Clin Invest 135(24). https:\/\/doi.org\/10.1172\/jci187627","DOI":"10.1172\/jci187627"},{"issue":"1","key":"12_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16244-2","volume":"11","author":"A Marchetto","year":"2020","unstructured":"Marchetto A, Ohmura S, Orth MF, Knott MML, Colombo MV, Arrigoni C et al. (2020) Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. Nat Commun 11(1):2423. https:\/\/doi.org\/10.1038\/s41467-020-16244-2","journal-title":"Nat Commun"},{"issue":"1","key":"12_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12071-2","volume":"10","author":"J Musa","year":"2019","unstructured":"Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O et al. (2019) Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nat Commun 10(1):4128. https:\/\/doi.org\/10.1038\/s41467-019-12071-2","journal-title":"Nat Commun"},{"issue":"2","key":"12_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1372-0","volume":"10","author":"M Dallmayer","year":"2019","unstructured":"Dallmayer M, Li J, Ohmura S, Alba Rubio R, Baldauf MC, H\u00f6lting TLB et al. (2019) Targeting the CALCB\/RAMP1 axis inhibits growth of Ewing sarcoma. Cell Death Dis 10(2):116. https:\/\/doi.org\/10.1038\/s41419-019-1372-0","journal-title":"Cell Death Dis"},{"issue":"1","key":"12_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25553-z","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Ohmura S, Marchetto A, Orth MF, Imle R, Dallmayer M et al. (2021) Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. Nat Commun 12(1):5356. https:\/\/doi.org\/10.1038\/s41467-021-25553-z","journal-title":"Nat Commun"},{"key":"12_CR32","unstructured":"Promega (2023) CellTiter-glo luminescent cell viability assay technical bulletin. Promega"},{"key":"12_CR33","unstructured":"Hall MP (1998) Stabilization of firefly luciferase using directed evolution. In: Proceedings of the 10th International Symposium on Bioluminescence and Chemiluminescence. pp 392\u2013395"},{"issue":"2","key":"12_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67\u201373. https:\/\/doi.org\/10.1177\/108705719900400206","journal-title":"J Biomol Screen"}],"container-title":["Methods in Molecular Biology","Ewing Sarcoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5587-0_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:54:28Z","timestamp":1792140868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/chapter\/10.1007\/978-1-0716-5587-0_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"ISBN":["9781071655863","9781071655870"],"references-count":34,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5587-0_12","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"16 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}